BrandWikiReturn

Empagliflozin/linagliptin

Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes.[4] It is a combination of empagliflozin and linagliptin.[4] It is taken by mouth.[4]

The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[4]

It was approved for use in the United States in January 2015,[5][6] for use in the European Union in November 2016,[7] and for use in Australia in December 2016.[8]

Medical uses

In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.[4]

In the European Union empagliflozin/linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus:[7]

  • to improve glycemic control when metformin and/or sulphonylurea (SU) and empagliflozin or linagliptin do not provide adequate glycemic control;[7]
  • when already being treated with the free combination of empagliflozin and linagliptin.[7]

Adverse effects

The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .[4][7] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).[7]

History

The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi.[9]

Further reading

References

  1. Empagliflozin / linagliptin (Glyxambi) Use During Pregnancy Drugs.com, 29 November 2018, retrieved 10 February 2020^
  2. Glyxambi 10 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC) (emc), 18 December 2019, retrieved 10 February 2020^
  3. Glyxambi 25 mg/5 mg Film-coated Tablets - Summary of Product Characteristics (SmPC) (emc), 18 December 2019, retrieved 10 February 2020^
  4. Glyxambi- empagliflozin and linagliptin tablet, film coated DailyMed, 22 January 2020, retrieved 3 April 2020^
  5. Glyxambi (empagliflozin and linagliptin) tablets U.S. Food and Drug Administration (FDA), 11 April 2016, retrieved 10 February 2020^
  6. Glyxambi: FDA-Approved Drugs U.S. Food and Drug Administration (FDA), retrieved 10 February 2020^
  7. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Glyxambi EPAR European Medicines Agency (EMA), 17 September 2018, retrieved 3 April 2020^
  8. Summary for ARTG Entry: 263557 Glyxambi 25 mg/5 mg empagliflozin/linagliptin 25mg/5mg film coated tablet blister pack Therapeutic Goods Administration (TGA)^
  9. Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes Am Health Drug Benefits, March 2015^